Together, our data indicate that sorafenib can effectively prevent the emergence of resistance in cancer cells addicted to mutant EGFR, but not in cells addicted to other driver mutations frequently found in NSCLC, such as those involving the oncogenes KRAS and ALK. The gene discussed is KRAS; the disease is cancer.